Ratings Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris Other stock markets 11:35:07 2024-05-03 am EDT			5-day change	1st Jan Change
14.06 ^EUR	+1.74%		-5.13%	+43.18%

Apr. 29	Abivax: share price rises as two analysts express optimism	CF
Apr. 29	Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the past year, analysts have significantly revised downwards their profit estimates.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABIVAX	+43.18%	953M	-
MODERNA, INC.	+25.69%	47.9B	B-
LONZA GROUP AG	+46.90%	41.42B	A
IQVIA HOLDINGS INC.	-3.46%	40.7B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B	B
BIO-TECHNE CORPORATION	+0.17%	12.15B	B+
MEDPACE HOLDINGS, INC.	+28.07%	12.14B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes